Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GLAXF SEC filings page on Stock Titan provides access to US regulatory documents filed by GSK plc, a global biopharma company. As a foreign private issuer, GSK submits an annual Form 20-F and frequent Form 6-K current reports under the Securities Exchange Act of 1934. These filings, sourced from EDGAR, cover product approvals, clinical trial outcomes, regulatory milestones and detailed transaction notifications for persons discharging managerial responsibilities (PDMRs).
For investors analysing GLAXF, GSK’s 6-K reports are a primary source of information on its vaccines, respiratory and immunology portfolio, and infectious disease pipeline. Recent filings describe European Commission approval of a prefilled syringe presentation for Shingrix, GSK’s recombinant zoster vaccine, and regulatory approvals in Japan for Exdensur (depemokimab) in severe asthma and chronic rhinosinusitis with nasal polyps. Other 6-Ks outline phase III B-Well 1 and B-Well 2 trial results for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B, including definitions of functional cure and key efficacy findings.
GSK’s filings also contain structured PDMR transaction notifications. These tables specify the financial instrument (ordinary shares of 31¼ pence each), ISIN (GB00BN7SWP63), nature of the transaction (such as acquisition of shares via dividend reinvestment or share reward plans), price, volume, date and trading venue (London Stock Exchange). This information allows users to track insider-related share dealings through Form 6-K disclosures.
On Stock Titan, each new GSK 6-K or 20-F is captured and can be paired with AI-powered summaries that explain the main points in plain language. Users can quickly identify filings related to vaccines, respiratory biologics, hepatology candidates or PDMR share activity, and then drill into the original documents for full legal and scientific detail.
GSK plc repurchased 170,000 ordinary shares on 05 November 2025 as part of its existing buyback programme, executed via BNP Paribas SA. Prices ranged from 1,779.00p to 1,798.00p with a volume‑weighted average price of 1,789.04p. The purchased shares will be held as treasury shares.
Since 30 September 2025, the company has purchased 7,819,000 ordinary shares. After this transaction, GSK holds 255,283,844 shares in treasury and has 4,060,139,755 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,060,139,755, and the percentage of voting rights attributable to treasury shares is 6.29 per cent.
GSK plc reported a routine share buyback under its existing programme. On 04 November 2025, the company repurchased 175,000 ordinary shares at prices between 1,747.00p and 1,790.00p, with a volume‑weighted average price of 1,768.39p. The shares will be held as Treasury shares.
The purchase was executed by BNP Paribas SA under a non‑discretionary agreement announced on 30 September 2025. Since 30 September 2025, 7,649,000 shares have been bought. After this transaction, GSK holds 255,113,844 shares in treasury and has 4,060,309,755 shares in issue (excluding treasury). The total number of voting rights is 4,060,309,755, and the percentage of voting rights attributable to treasury shares is 6.28%.
GSK plc reported a routine share buyback under its non‑discretionary agreement with BNP Paribas SA. On 03 November 2025, the company purchased 170,500 ordinary shares of 31¼ pence each at a lowest price 1,758.50p, highest price 1,782.00p, and volume‑weighted average price (VWAP) 1,769.85p. The shares will be held as Treasury shares and form part of the existing buyback programme announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 7,474,000 ordinary shares. After the latest transaction, GSK holds 254,938,844 shares in treasury and has 4,060,484,755 ordinary shares in issue (excluding treasury). The total voting rights are 4,060,484,755, and the percentage of voting rights attributable to treasury shares is 6.28%.
GSK plc reported its monthly total voting rights and capital. As at 31 October 2025, the company had 4,315,423,599 Ordinary Shares of 31 ¼ pence each in issue, of which 254,768,344 were held in treasury. The resulting total number of voting rights is 4,060,655,255.
Shareholders may use this voting rights figure as the denominator when assessing whether they must notify holdings or changes under the FCA’s Disclosure Guidance and Transparency Rules.
GSK plc reported a share buyback transaction executed via BNP Paribas SA, purchasing 175,000 ordinary shares on 31 October 2025. Prices ranged from 1,760.00p to 1,791.50p with a volume‑weighted average price of 1,780.09p. The shares will be held as Treasury shares as part of the Company’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025. Since 30 September 2025, the Company has purchased 7,303,500 shares.
After this purchase, GSK holds 254,768,344 shares in treasury and has 4,060,655,255 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,060,655,255, and treasury shares represent 6.27% of voting rights. The filing also provides a venue‑level breakdown and individual trade details for trades on XLON, CHIX and BATE.
GSK plc reported a daily share repurchase under its existing buyback programme. On 30 October 2025, the company bought 180,000 ordinary shares at prices between 1,726.50p and 1,780.00p, with a volume-weighted average price of 1,756.23p. The shares will be held as treasury shares.
Since 30 September 2025, GSK has purchased 7,128,500 ordinary shares. Following this transaction, GSK holds 254,593,344 ordinary shares in treasury and has 4,060,827,442 ordinary shares in issue (excluding treasury shares). The total number of voting rights is 4,060,827,442, and the percentage of voting rights attributable to treasury shares is 6.27%.
GSK plc reported dealings by two senior executives. Regis Simard sold 37,000 Ordinary Shares at £16.8395 per share, and Deborah Waterhouse sold 120,000 Ordinary Shares at £16.8865 per share. Both transactions were single trades executed on the London Stock Exchange on 2025-10-29.
GSK plc repurchased 180,000 ordinary shares on
Since
GSK plc reported a routine share repurchase under its existing buyback programme. On 28 October 2025, the company bought 320,000 ordinary shares at prices between 1,634.00p and 1,655.00p, with a volume‑weighted average price of 1,644.29p. The shares will be held as treasury shares and the purchases were executed by BNP Paribas SA under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 6,768,500 shares. Following this transaction, GSK holds 254,233,344 shares in treasury and has 4,061,187,442 shares in issue (excluding treasury shares), which is also the total number of voting rights. The percentage of voting rights attributable to treasury shares is 6.26%. Aggregated venue volumes for the day were BATE 44,453, CHIX 44,604, and XLON 230,943.
GSK reported a strong Q3, with turnover of £8,547 million (+8% CER) and Core EPS of 55.0p (+14% CER). Total operating profit and Total EPS rose by over 100%, helped by lower Significant legal expenses, lower CCL charges and higher other operating income. Cash generated from operations was £2,520 million and free cash flow was £1,246 million.
Growth was broad-based: Specialty Medicines £3,409 million (+16% CER) led by HIV (£1,944 million, +12% CER) and Oncology (£511 million, +39% CER); Vaccines £2,678 million (+2% CER) with Shingrix £830 million (+13% CER) and Arexvy £251 million (+36% CER); General Medicines £2,460 million (+4% CER) with Trelegy £736 million (+25% CER). GSK upgraded 2025 guidance at CER to turnover growth of 6–7%, Core operating profit growth of 9–11%, and Core EPS growth of 10–12%. The company declared a 16p Q3 dividend (64p expected for 2025) and has spent £1.1 billion YTD toward its £2 billion share buyback.
FAQ
What is the current stock price of GSK PLC (GLAXF)?
